Literature DB >> 11743050

Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays.

C V Hedvat1, E S Jaffe, J Qin, D A Filippa, C Cordon-Cardo, G Tosato, S D Nimer, J Teruya-Feldstein.   

Abstract

Hodgkin's disease (HD) is a lymphoid malignancy characterized by the presence of Reed-Sternberg (RS) and Hodgkin's cells in a background of mixed inflammatory cells and stromal reaction. Studies have documented that HD is a neoplasm associated with abnormal cytokine and chemokine production. To define the expression of macrophage-derived chemokine (MDC) in HD, 57 cases (18 lymphocyte predominant, 11 mixed cellularity, 28 nodular sclerosis) were stained for MDC by immunohistochemistry and compared with reactive lymph nodes as controls. MDC was expressed by RS cells in classical HD (CHD) and showed a distinct cytoplasmic and Golgi localization. Accumulating evidence suggests that lymphocyte-predominant HD (LPHD) represents an entity distinct from CHD, with different biological properties and clinical course. On the basis of the high level of MDC staining alone, CHD could be distinguished from LPHD (P <.001), which showed only faint staining of scattered histiocytes similar to control tissues. CHD cases with high MDC mRNA levels showed high levels of MDC protein expression by immunohistochemistry (P <.001) and significant eosinophil infiltration, suggesting that MDC may represent another molecule that plays a critical role in eosinophil recruitment. We also analyzed 102 cases of non-Hodgkin's lymphoma and normal spleen, lymph node, and thymic tissue. High levels of MDC expression were specific to CHD cases because only low levels of MDC were observed in a minor subset of LPHD, NHL or normal lymphoid tissues.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11743050     DOI: 10.1038/modpathol.3880473

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  12 in total

1.  Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure.

Authors:  Marylène Lejeune; Joaquín Jaén; Lluis Pons; Carlos López; Maria-Teresa Salvadó; Ramón Bosch; Marcial García; Patricia Escrivà; Jordi Baucells; Xavier Cugat; Tomás Alvaro
Journal:  J Anat       Date:  2008-06       Impact factor: 2.610

2.  Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin's lymphoma.

Authors:  Katalin Keresztes; Zoltan Szollosi; Zsofia Simon; Ilona Tarkanyi; Zoltan Nemes; Arpad Illes
Journal:  Pathol Oncol Res       Date:  2007-10-07       Impact factor: 3.201

Review 3.  Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Authors:  Nathan H Fowler; Chan Yoon Cheah; Randy D Gascoyne; John Gribben; Sattva S Neelapu; Paolo Ghia; Catherine Bollard; Stephen Ansell; Michael Curran; Wyndham H Wilson; Susan O'Brien; Cliona Grant; Richard Little; Thorsten Zenz; Loretta J Nastoupil; Kieron Dunleavy
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

4.  Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells.

Authors:  Paul Greaves; Andrew Clear; Andrew Owen; Sameena Iqbal; Abigail Lee; Janet Matthews; Andrew Wilson; Maria Calaminici; John G Gribben
Journal:  Blood       Date:  2013-09-04       Impact factor: 22.113

5.  Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Authors:  Eric D Hsi; Hongli Li; Andrew B Nixon; Heiko Schöder; Nancy L Bartlett; Michael LeBlanc; Sonali Smith; Brad S Kahl; John P Leonard; Andrew M Evens; David W Scott; Lisa M Rimsza; Jonathan W Friedberg
Journal:  Blood       Date:  2019-02-05       Impact factor: 22.113

Review 6.  Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies.

Authors:  Michael R Cook; Kieron Dunleavy
Journal:  Curr Oncol Rep       Date:  2022-04-11       Impact factor: 5.945

7.  Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells.

Authors:  Karl R N Baumforth; Anna Birgersdotter; Gary M Reynolds; Wenbin Wei; Georgia Kapatai; Joanne R Flavell; Emma Kalk; Karen Piper; Steve Lee; Lee Machado; Kerry Hadley; Anne Sundblad; Jan Sjoberg; Magnus Bjorkholm; Anna A Porwit; Lee-Fah Yap; Soohwang Teo; Richard G Grundy; Lawrence S Young; Ingemar Ernberg; Ciaran B J Woodman; Paul G Murray
Journal:  Am J Pathol       Date:  2008-05-23       Impact factor: 4.307

8.  The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma.

Authors:  Aashiyana F Koreishi; Adam J Saenz; Dan O Persky; Hayan Cui; Allison Moskowitz; Craig H Moskowitz; Julie Teruya-Feldstein
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-05

9.  Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells.

Authors:  Hitoshi Hanamoto; Takashi Nakayama; Hajime Miyazato; Sumio Takegawa; Kunio Hieshima; Yoichi Tatsumi; Akihisa Kanamaru; Osamu Yoshie
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

10.  CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo.

Authors:  Jonathan M Eby; Hee-Kap Kang; Sean T Tully; Wendy E Bindeman; Daniel S Peiffer; Shilpak Chatterjee; Shikhar Mehrotra; I Caroline Le Poole
Journal:  J Invest Dermatol       Date:  2015-01-09       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.